NASDAQ
19.39USD
-0.45 (-2.27%)
We have scored 7 news catalysts on Nuvectis Pharma, Inc. (NVCT) over the past 12 months. The biggest single-day move next to one of them came Jun 30, 2026, when NVCT closed −35.5%: “Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock”. Coverage across the window leans positive (average ticker sentiment +0.57). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
666.8M
P/E
—
EPS
—
Beta
-0.24
52W range
5.77-29.28
Day range
19.05–20.09
Open
19.81
Prev close
19.84
Volume
301.6K
Avg volume
211.6K
Dividend
0.00
IPO
2022-02-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Nuvectis Pharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NVCT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.